2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Bradley McGregor, MD, discusses the need to develop novel, actionable targets in renal cell carcinoma.
Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the need to develop novel, actionable targets in renal cell carcinoma (RCC).
Although the treatment landscape of RCC features effective combination regimens, some patients still experience disease progression, explains McGregor.
At the 2020 ASCO Virtual Scientific Program, data from a phase 2 trial (NCT03401788) evaluating the investigational oral hypoxia-inducible factor (HIF)-2α inhibitor MK-6482 demonstrated promising clinical activity and tolerability in patients with treatment-naïve Von Hippel-Lindau disease–associated RCC.
Moreover, a phase 3 study (NCT04195750) is evaluating MK-6482 versus everolimus (Afinitor) in patients with advanced RCC, concludes McGregor.